Dalgleish A G, Woods R L, Levi J A, Raghavan D, McCaughan G W, Tattersall M H
Aust N Z J Med. 1983 Dec;13(6):605-7. doi: 10.1111/j.1445-5994.1983.tb02613.x.
Fifty-three patients with Hepatocellular Carcinoma (HCC) from three Sydney teaching hospitals were examined for possible evidence of Hepatitis B virus (HBV) infection. Hepatitis Surface Antigen (HBsAg) was positive in 38% of those in whom it was sought, a higher incidence than previously reported in an Australian series. A further 13 patients had antibody to Hepatitis B core (Anti-HBc), but negative HBsAg, confirming past exposure to HBV. Where serum was available evidence of HBV infection was obtained in 62% of patients. It is argued that the incidence of HBV infection may be shown to be higher still with the advent of new technology as applied to HBV assays and tissue stains. The need to be aware of the growing evidence of a strong association between Hepatitis B virus and the development of HCC is stressed and the clinical implications are discussed.
来自悉尼三家教学医院的53例肝细胞癌（HCC）患者接受了检查，以寻找乙型肝炎病毒（HBV）感染的可能证据。在接受检测的患者中，38%的人乙型肝炎表面抗原（HBsAg）呈阳性，这一发生率高于此前澳大利亚系列报道。另有13名患者乙型肝炎核心抗体（抗-HBc）呈阳性，但HBsAg呈阴性，证实曾接触过HBV。在有血清样本的患者中，62%的人获得了HBV感染的证据。有人认为，随着应用于HBV检测和组织染色的新技术的出现，HBV感染的发生率可能会更高。强调了有必要认识到越来越多的证据表明乙型肝炎病毒与HCC的发生之间存在密切关联，并讨论了其临床意义。
